Search

Your search keyword '"de Mestier, Louis"' showing total 8 results
Start Over Author "de Mestier, Louis" Publisher bioscientifica
8 results on '"de Mestier, Louis"'

1. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs

Author

de Mestier, Louis, primary, Lamarca, Angela, additional, Hernando, Jorge, additional, Zandee, Wouter, additional, Alonso-Gordoa, Teresa, additional, Perrier, Marine, additional, Walenkamp, Annemiek ME, additional, Chakrabarty, Bipasha, additional, Landolfi, Stefania, additional, Van Velthuysen, Marie-Louise F, additional, Kats-Ugurlu, Gursah, additional, Caminoa, Alejandra, additional, Ronot, Maxime, additional, Manoharan, Prakash, additional, Garcia-Alvarez, Alejandro, additional, Brabander, Tessa, additional, García Gómez-Muriel, María Isabel, additional, Cadiot, Guillaume, additional, Couvelard, Anne, additional, Capdevila, Jaume, additional, Pavel, Marianne E, additional, and Cros, Jérôme, additional

Published
2021
Full Text
View/download PDF

2. Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors

Author

De Rycke, Ophélie, primary, Walter, Thomas, additional, Perrier, Marine, additional, Hentic, Olivia, additional, Lombard-Bohas, Catherine, additional, Coriat, Romain, additional, Cadiot, Guillaume, additional, Couvelard, Anne, additional, Ruszniewski, Philippe, additional, Cros, Jérôme, additional, and de Mestier, Louis, additional

Published
2021
Full Text
View/download PDF

4. Tumour growth rate (TGR) in neuroendocrine tumours (NETs): changes following systemic treatment and external validation of previous findings; the GREPONET-2 study

Author

Lamarca, Angela, primary, Ronot, Maxime, additional, Moalla, Salma, additional, Crona, Joakim, additional, Opalinska, Marta, additional, Lopez-Lopez, Carlos, additional, Pezzutti, Daniela, additional, Najran, Pavan, additional, Carvhalo, Luciana, additional, Otaviano, Franca Bezerra Regis, additional, Borg, Philip, additional, Vietti-Violi, Naik, additional, Vidal-Trueba, Hector, additional, de, Mestier Louis, additional, Scaefer, Niklaus, additional, Baudin, Eric, additional, Sundin, Anders, additional, Costa, Frederico, additional, Pavel, Marianne, additional, and Dromain, Clarisse, additional

Published
2018
Full Text
View/download PDF

7. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art

Author

de Mestier, Louis, primary, Dromain, Clarisse, additional, d'Assignies, Gaspard, additional, Scoazec, Jean-Yves, additional, Lassau, Nathalie, additional, Lebtahi, Rachida, additional, Brixi, Hedia, additional, Mitry, Emmanuel, additional, Guimbaud, Rosine, additional, Courbon, Frédéric, additional, d'Herbomez, Michèle, additional, and Cadiot, Guillaume, additional

Published
2013
Full Text
View/download PDF

8. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art.

Author

de Mestier L, Dromain C, d'Assignies G, Scoazec JY, Lassau N, Lebtahi R, Brixi H, Mitry E, Guimbaud R, Courbon F, d'Herbomez M, and Cadiot G

Subjects
Animals, Disease Progression, Gastrointestinal Neoplasms pathology, Humans, Neuroendocrine Tumors pathology, Gastrointestinal Neoplasms therapy, Molecular Targeted Therapy, Neuroendocrine Tumors therapy
Abstract

Well-differentiated neuroendocrine tumors (NETs) are a group of heterogeneous rare tumors. They are often slow-growing and patients can have very long survival, even at the metastatic stage. The evaluation of tumor progression and therapeutic responses is currently based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST) criteria. As for other malignancies, RECIST criteria are being reexamined for NETs in the era of targeted therapies because tumor response to targeted therapies is rarely associated with shrinkage, as opposed to prolonged progression-free survival. Therefore, size-based criteria no longer seem to be suitable to the assessment of NET progression and therapeutic responses, especially considering targeted therapies. New imaging criteria, combining morphological and functional techniques, have proven relevant for other malignancies treated with targeted therapies. To date, such studies have rarely been conducted on NETs. Moreover, optimizing the management of NET patients also requires considering clinical, biological, and pathological aspects of tumor evolution. Our objectives herein were to comprehensively review current knowledge on the assessment of tumor progression and early prediction of therapeutic responses and to broaden the outlook on well-differentiated NETs, in the era of targeted therapies.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results